Keyword: Nektar Therapeutics
Nektar is a multibillion-dollar biotech with most of its value tied to a single drug—and that drug doesn’t work, claims Plainview.
Martin Shkreli, infamous for his combative tweets and general "insolent" demeanor, may be blogging biopharma tips from prison.
Nektar’s much-anticipated data from a study pairing its NKTR-214 with Bristol-Myers Squibb’s Opdivo have resulted in a lot of head-scratching.
Syndax’s shares slid after an ASCO abstract revealed lackluster data with entinostat, but it's forging ahead with a new combination study with Nektar.
The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers.
Takeda has paired with Nektar to work on a new immuno-oncology combination trial.
The AACR conference featured data on promising new approaches to CAR-T treatments and stimulating cancer-killing immune cells.
The takeover will give Merck control of an oncolytic immunotherapy that Viralytics is testing in combination with Keytruda in early-phase trials.
Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.
Nektar Therapeutics could join the growing list of biotechs opting for a takeover, according to a report that it is exploring strategic options.